{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:59:23Z","timestamp":1787605163933,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T00:00:00Z","timestamp":1409270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Almirall"},{"name":"Actelion"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Cutaneous T\u2010cell lymphoma (CTCL<\/jats:styled-content>) is a potentially life\u2010limiting malignant disease. Treatment strategies in CTCL<\/jats:styled-content> aim at disease control and remission with the lowest possible side\u2010effects.<\/jats:p><\/jats:sec>Objective<\/jats:title>Recent reports suggest that the new vitamin A derivative alitretinoin might be a well\u2010tolerated treatment option.<\/jats:p><\/jats:sec>Methods<\/jats:title>We analysed the files of 11 CTCL<\/jats:styled-content> patients with mycosis fungoides (n\u00a0<\/jats:italic>=\u00a0<\/jats:italic>10) or S\u00e9zary syndrome (n\u00a0<\/jats:italic>=\u00a0<\/jats:italic>1), who were treated with oral alitretinoin alone or in combination with standard treatment based on individual off\u2010label treatment decisions. Patients had been monitored every 4\u20138\u00a0weeks with skin examination and laboratory analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>Ten of 11 patients (90.9%) showed a marked improvement of their CTCL<\/jats:styled-content> skin lesions and no progress of the disease during treatment with alitretinoin, one patient showed no response to the treatment (9.1%). Four of the responding patients (40.0%) had a complete response and 6 (60.0%) had a partial response. Average time to response was 2.5\u00a0months. Duration of treatment varied depending on whether patients had reached complete or partial remission. In general, alitretinoin was well tolerated. One of 11 patients developed high non\u2010fasting average serum cholesterol (>300\u00a0mg\/dL) and 1\/11 a mean non\u2010fasting triglyceride value >500\u00a0mg\/dL. In 3\/11 patients, thyroid\u2010stimulating hormone declined without clinical symptoms during treatment, with one of the patients also showing a decreased thyroxin level.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>In our group of CTCL<\/jats:styled-content> patients we noticed a low rate of side\u2010effects and an overall good clinical response to treatment with alitretinoin. Further studies are required to substantiate this early clinical observation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12684","type":"journal-article","created":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T13:46:39Z","timestamp":1409319999000},"page":"783-788","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of cutaneous T\u2010cell lymphoma with oral alitretinoin"],"prefix":"10.1111","volume":"29","author":[{"given":"C.","family":"Kapser","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Herzinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Flaig","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Molin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06450.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60420-1"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0379.2012.8018_5.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09475.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.05.011"},{"key":"e_1_2_5_7_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1684\/ejd.2012.1857","article-title":"Combined oral alitretinoin and narrowband UVB treatment of cutaneous T cell lymphoma: favourable response after multiple ineffective systemic therapies","volume":"22","author":"Motschenbacher S","year":"2012","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00083.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900496b"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.3.437"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001050-00005"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1453"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08487.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-010-2043-3"},{"key":"e_1_2_5_15_1","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early\u2010stage cutaneous T\u2010cell lymphoma","volume":"137","author":"Duvic M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.07.013"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/ddg.12166","article-title":"Alitretinoin: an effective treatment option for pagetoid reticulosis","volume":"11","author":"Schmitz L","year":"2013","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:23:24Z","timestamp":1695471804000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,29]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/jdv.12684"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12684","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,29]]}}}